In 2012, the U.S. Preventative Service Task Force (USPSTF) released a controversial recommendation about prostate-specific antigen (PSA) screening, a blood test that may signal prostate cancer. According to the statement, men were encouraged to not undergo a routine PSA screening because the potential harms ­— including false-positive results, over diagnosis, and treatment complications like erectile dysfunction — outweighed the benefits. In 2018, however, the USPSTF updated its directive. The USPSTF now does not recommend PSA-based prostate cancer screening for men over the age of 70.